Pfizer Inc. $PFE Shares Bought by Significant Wealth Partners LLC

Significant Wealth Partners LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 13.5% during the second quarter, HoldingsChannel reports. The firm owned 9,476 shares of the biopharmaceutical company’s stock after buying an additional 1,127 shares during the period. Significant Wealth Partners LLC’s holdings in Pfizer were worth $230,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Jeppson Wealth Management LLC increased its stake in Pfizer by 13.3% in the second quarter. Jeppson Wealth Management LLC now owns 37,526 shares of the biopharmaceutical company’s stock valued at $910,000 after purchasing an additional 4,411 shares during the period. Penn Davis Mcfarland Inc. increased its stake in Pfizer by 20.3% in the second quarter. Penn Davis Mcfarland Inc. now owns 120,365 shares of the biopharmaceutical company’s stock valued at $2,918,000 after purchasing an additional 20,295 shares during the period. McAdam LLC increased its stake in Pfizer by 5.4% in the second quarter. McAdam LLC now owns 13,674 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 706 shares during the period. Pitti Group Wealth Management LLC boosted its holdings in shares of Pfizer by 4.9% in the second quarter. Pitti Group Wealth Management LLC now owns 15,928 shares of the biopharmaceutical company’s stock valued at $386,000 after acquiring an additional 742 shares in the last quarter. Finally, Well Done LLC increased its stake in shares of Pfizer by 4.4% during the second quarter. Well Done LLC now owns 12,433 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 527 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, September 20th. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Stock Down 0.3%

PFE stock opened at $24.07 on Thursday. The company has a market cap of $136.82 billion, a P/E ratio of 12.80, a P/E/G ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company’s 50-day moving average price is $24.59 and its 200 day moving average price is $24.18. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.